PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS

Bibliographic Details
Main Authors:	Martine Allard, Cecile Krejsa, Isaiah Williams, Terry Podoll, Kim Steinmann, Greg Slatter
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000975552.36170.ba

Similar Items

PB2205: A MECHANISTIC ABSORPTION AND PHARMACOKINETIC MODEL OF COVALENT BTK INHIBITOR TL-895: INFLUENCE OF FOOD AND ACID REDUCING AGENTS
by: Joyce Macwan, et al.
Published: (2023-08-01)

P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)
by: Michael Gulrajani, et al.
Published: (2023-08-01)

P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING
by: Subbaiah Chary Nimmagadda, et al.
Published: (2023-08-01)

P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)
by: Michael Loschi, et al.
Published: (2023-08-01)

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
by: Francesca Palandri, et al.
Published: (2023-08-01)

Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)—an analysis of an administrative health claims database
by: Srilakshmi Vallabhaneni, et al.
Published: (2024-06-01)

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia
by: Daniel Medina-Gil, et al.
Published: (2025-03-01)

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
by: Danling Gu, et al.
Published: (2021-03-01)

P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)
by: Bijal Shah, et al.
Published: (2023-08-01)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
by: Xiaoyu Feng, et al.
Published: (2023-08-01)

Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia
by: Anna Maria Frustaci, et al.
Published: (2025-02-01)

Expression of Bruton's tyrosine kinase in osteoclasts
by: Danks, L, et al.
Published: (2005)

Editorial: Targeting Bruton Tyrosine Kinase
by: Cornelia Brunner, et al.
Published: (2022-04-01)

Targeting Bruton’s Tyrosine Kinase in CLL
by: Inhye E. Ahn, et al.
Published: (2021-06-01)

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants
by: Sibel Ucpinar, et al.
Published: (2023-07-01)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
by: Longfei Zhang, et al.
Published: (2022-03-01)

Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase.
by: Hong Ma, et al.
Published: (2013-01-01)

Second-generation inhibitors of Bruton tyrosine kinase
by: Jingjing Wu, et al.
Published: (2016-09-01)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
by: Xianhui Wang, et al.
Published: (2021-07-01)

SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE I AND II CLINICAL TRIALS: SAFETY AND EFFICACY OF ANTI-CD19 CAR-T CELL THERAPY IN COMBINATION WITH BRUTON'S TYROSINE KINASE INHIBITORS (BTKI) FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
by: KAM Martins, et al.
Published: (2024-10-01)

P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
by: Masoom Priyadarshini, et al.
Published: (2023-08-01)

PB2696: QUALITATIVE INTERVIEWS TO DESCRIBE BURDEN IN PATIENTS (PT) WITH THIRD-LINE OR LATER CLL/SLL WITH PRIOR EXPOSURE TO BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
by: Masoom Priyadarshini, et al.
Published: (2023-08-01)

2200
by: Susan Lynn Murphy, et al.
Published: (2017-09-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)

Role of Bruton’s tyrosine kinase in B cells and malignancies
by: Simar Pal Singh, et al.
Published: (2018-02-01)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
by: C. I. Edvard Smith, et al.
Published: (2021-11-01)

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
by: John N. Allan, et al.
Published: (2021-12-01)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
by: Heather Zhang, et al.
Published: (2021-12-01)

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
by: Idanna Innocenti, et al.
Published: (2024-12-01)

Role of Bruton's Tyrosine Kinase in B Cell Development
by: Alex Maas, et al.
Published: (2001-01-01)

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
by: Laura Airas, et al.
Published: (2024-04-01)

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
by: Simar Pal Singh, et al.
Published: (2019-04-01)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
by: Arneson LC, et al.
Published: (2021-08-01)

Magyarország kultúrgeográfiai korszakai (895–1920)
by: Frisnyák Sándor
Published: (1996-03-01)

Molecules 2002, 7, 885-895
by: Dr. Derek McPhee
Published: (2006-05-01)

Covalent cysteine targeting of Bruton’s tyrosine kinase (BTK) family by withaferin-A reduces survival of glucocorticoid-resistant multiple myeloma MM1 cells
by: Logie, Emilie, et al.
Published: (2021)

Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison
by: Othman Al-Sawaf, et al.
Published: (2023-11-01)

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
by: Rhodes JM, et al.
Published: (2021-03-01)

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema
by: Shannon Meledathu, BS, et al.
Published: (2024-12-01)

PROTAC for Bruton’s tyrosine kinase degradation alleviates inflammation in autoimmune diseases
by: Can Zhu, et al.
Published: (2024-08-01)